PL EN


Preferences help
enabled [disable] Abstract
Number of results
2019 | 123 | 181-191
Article title

JULUCA - a new therapeutic opportunity for patients infected with HIV-1

Content
Title variants
Languages of publication
EN
Abstracts
EN
Although there are currently known treatments for AIDS patients, the virus is still evolving, which means that it is not always possible to eradicate it from an infected organism. The FDA approved in November 2017 the first, complete treatment regimen containing two drugs: dolutegravir and rilpivirine (Juluca). The following article discusses current knowledge about a new, innovative drug as well as future therapeutic options of HIV-1 patients. The preparation can be used as a complete treatment regimen for HIV-1 infection to replace the current antiretroviral regimen in adults who have been virologically inhibited for at least 6 months. Clinical studies of this preparation show that the drug is well tolerated, is metabolizable and offers additional benefits, such as improving the lipid profile, improving bone mineral density and reduced bone resorption. Undoubtedly, longer observation of the effects of this drug therapy is needed, but this dual scheme seems to be a promising strategy for patients infected with HIV.
Keywords
Discipline
Year
Volume
123
Pages
181-191
Physical description
Contributors
  • Department of Applied Psychology, Medical University of Lublin, Poland
  • Department of Applied Psychology, Medical University of Lublin, Poland
  • Department of Applied Psychology, Medical University of Lublin, Poland
author
  • Department of Applied Psychology, Medical University of Lublin, Poland
  • Department of Applied Psychology, Medical University of Lublin, Poland
  • Department of Applied Psychology, Medical University of Lublin, Poland
  • Department of Applied Psychology, Medical University of Lublin, Poland
References
  • [1] D. Ray. Juluca - a two-drug complete regimen for HIV. Med Lett Drugs Ther. 60 (2018) e202-e204
  • [2] J. C. Plantier, M. Leoz, J.E. Dickerson, et al. A new human immunodeficiency virus derived from gorillas. Nat Med. 15 (2009) 871-872
  • [3] M. J. Ward, S. J. Lycett, M. L. Kalish, et al. Estimating the rate of intersubtype recombination in early HIV-1 group M strains. J Virol. 87 (2013) 1967-197
  • [4] J. R. Perilla, K. Schulten. Physical properties of the HIV-1 capsid from all-atom molecular dynamics simulations. Nat Commun. 8 (2017) 15959
  • [5] E. M. Campbell, T. J. Hope. HIV-1 capsid: the multifaceted key player in HIV-1 infection. Nat Rev Microbiol. 13 (2015) 471-483
  • [6] D. K. Maheshwari. A Textbook of Microbiology. S. Chand Publishing. 3 (1999) 478-480
  • [7] N. Ray, R. W. Doms. HIV-1 coreceptors and their inhibitors. Curr Top Microbiol Immunol. 303 (2006) 97-120
  • [8] C. Chawla, S. S. Sahoo, R. Jain, et al. HIV: is a vaccine the answer? Hum Vaccin Immunother. 10 (1) (2014) 238-240
  • [9] Brodziak. HIV and AIDS - contemporary dilemmas. Annales Academiae Medicae. Silesiensis 65 (2011) 38-47
  • [10] M. J. Ward, S. J. Lycett, M. L. Kalish, et al. Estimating the rate of intersubtype recombination in early HIV-1 group M strains. J Virol. 87 (2013) 1967-1973
  • [11] J. R. Perilla, K. Schulten. Physical properties of the HIV-1 capsid from all-atom molecular dynamics simulations. Nat Commun. 8 (2017) 34-45
  • [12] V. Le Sage, A. J. Mouland, F. Valiente-Echeverria. Roles of HIV-1 capsid in viral replication and immune evasion. Virus Res. 193 (2014) 116-129
  • [13] V. Simon, D.D. Ho, Q. A. Karim. HIV/AIDS epidemiology, pathogenesis, prevention and treatment. Lancet. 368 (9534) (2006) 489-504
  • [14] S. Hosek, A. Pettifor. HIV Prevention Interventions for Adolescents. Curr HIV/AIDS Rep. 1 (2019) 143-155
  • [15] E.G. Kostaki, D. Frampton, D. Paraskevis, et al. Near full-length genomic sequencing and molecular analysis of HIV-infected individuals in a network-based intervention (TRIP) in Athens, Greece: Evidence that transmissions occur more frequently from those with high HIV-RNA. Curr HIV Res. 30 (2019) 471-483
  • [16] B.M. Mathers, L. Degenhardt, B. Phillips, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372 (9651) (2008) 1733-45
  • [17] K.M. De Cock, H.W. Jaffe, J. W. Curran. The evolving epidemiology off hiv/aids. AIDS 26 (10) (2012) 1205-13
  • [18] H. A. Blair. Dolutegravir/Rilpivirine: A Review in HIV-1 Infection. Drugs. 78 (16) (2018) 1741-1750
  • [19] J.L. Revuelta-Herrero, E. Chamorro-de-Vega, C.G. Rodríguez-González, et al. Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients. Ann Pharmacother. 52 (1) (2018) 11-18
  • [20] J.L. Casado, M. Monsalvo, A.M. Rojo, et al. Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection. Expert Rev Clin Pharmacol. 11 (6) (2018) 561-570
  • [21] M. Properzi, P. Magro, F. Castelli, et al. Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults. Expert Rev Anti Infect Ther. 16 (12) (2018) 877-887
  • [22] F. Capetti, M. V. Cossu, L. Paladini, et al. Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection. Expert Opin Pharmacother. 19 (1) (2018) 65-77
  • [23] F. Capetti, N. Astuti, D. Cattaneo, et al. Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV. Expert Opin Drug Metab Toxicol. 13 (11) (2017) 1183-1192
  • [24] Amedeo F. Capetti, Maria V. Cossu, Laura Paladini i Giuliano Rizzardini. Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection. Expert Opinion on Pharmacotherapy Volume 19, 2018 - Issue 1, 65-77
  • [25] Jose L. Casado, Marta Monsalvo, Aurora M. Rojo, María Fontecha i Miguel A. Rodriguez-Sagrado (2018). Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection. Expert Review of Clinical Pharmacology, 11: 6, 561-570. https://doi.org/10.1080/17512433.2018.1478726
  • [26] Orrell, D.P Hagins, E. Belonosova, et al. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. Lancet HIV 4 (12) (2017) e536-e546
  • [27] P. Arrabal-Durán, C.G. Rodríguez-González, E. Chamorro-de-Vega, et al. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks. Int J Clin Pract. 71 (8) (2017)
  • [28] E. Ribera. New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy. AIDS Rev. 2018; 20(4): 179-186. doi: 10.24875/AIDSRev.M18000026
  • [29] J. M. Llibre, C.C. Hung, C. Brinson, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 3 (2018) 391-3
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-98067558-e058-4d65-bb86-d8c9398159fc
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.